Table of Content

1 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Overview
1.1 Product Overview and Scope of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine
1.2 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Segment by Type
1.2.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Value Comparison by Type (2024-2034)
1.2.2 Nasal Spray
1.2.3 Chest Injection
1.2.4 Intramuscular Injection
1.2.5 Intrapulmonary Injection
1.3 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Segment by Application
1.3.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Value by Application: (2024-2034)
1.3.2 Piglets
1.3.3 Adults Pigs
1.4 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Size Estimates and Forecasts
1.4.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue 2024-2034
1.4.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales 2024-2034
1.4.3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Average Price (2024-2034)
1.5 Assumptions and Limitations
2 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Competition by Manufacturers
2.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Manufacturers (2024-2024)
2.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Manufacturers (2024-2024)
2.3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Average Price by Manufacturers (2024-2024)
2.4 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine, Product Type & Application
2.7 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Competitive Situation and Trends
2.7.1 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Players Market Share by Revenue
2.7.3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Retrospective Market Scenario by Region
3.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Size by Region: 2024 Versus 2022 Versus 2034
3.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Region: 2024-2034
3.2.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Region: 2024-2024
3.2.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Region: 2024-2034
3.3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Region: 2024-2034
3.3.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Region: 2024-2024
3.3.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Region: 2024-2034
3.4 North America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Facts & Figures by Country
3.4.1 North America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.4.2 North America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2024-2034)
3.4.3 North America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2024-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Facts & Figures by Country
3.5.1 Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.5.2 Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2024-2034)
3.5.3 Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2024-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.6.2 Asia Pacific Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2024-2034)
3.6.3 Asia Pacific Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2024-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Facts & Figures by Country
3.7.1 Latin America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.7.2 Latin America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2024-2034)
3.7.3 Latin America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2024-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Size by Country: 2024 VS 2022 VS 2034
3.8.2 Middle East and Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2024-2034)
3.8.3 Middle East and Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2024-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type (2024-2034)
4.1.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type (2024-2024)
4.1.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Type (2024-2034)
4.1.3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type (2024-2034)
4.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Type (2024-2034)
4.2.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Type (2024-2024)
4.2.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Type (2024-2034)
4.2.3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Type (2024-2034)
4.3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Price by Type (2024-2034)
5 Segment by Application
5.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application (2024-2034)
5.1.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application (2024-2024)
5.1.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Application (2024-2034)
5.1.3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Application (2024-2034)
5.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Application (2024-2034)
5.2.1 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Application (2024-2024)
5.2.2 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Application (2024-2034)
5.2.3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Application (2024-2034)
5.3 Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Price by Application (2024-2034)
6 Key Companies Profiled
6.1 Zoetis Animal Health
6.1.1 Zoetis Animal Health Corporation Information
6.1.2 Zoetis Animal Health Description and Business Overview
6.1.3 Zoetis Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.1.4 Zoetis Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.1.5 Zoetis Animal Health Recent Developments/Updates
6.2 Boehringer-Ingelheim
6.2.1 Boehringer-Ingelheim Corporation Information
6.2.2 Boehringer-Ingelheim Description and Business Overview
6.2.3 Boehringer-Ingelheim Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.2.4 Boehringer-Ingelheim Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.2.5 Boehringer-Ingelheim Recent Developments/Updates
6.3 Eurovet
6.3.1 Eurovet Corporation Information
6.3.2 Eurovet Description and Business Overview
6.3.3 Eurovet Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.3.4 Eurovet Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.3.5 Eurovet Recent Developments/Updates
6.4 Hipra
6.4.1 Hipra Corporation Information
6.4.2 Hipra Description and Business Overview
6.4.3 Hipra Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Hipra Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.4.5 Hipra Recent Developments/Updates
6.5 Merck Animal Health
6.5.1 Merck Animal Health Corporation Information
6.5.2 Merck Animal Health Description and Business Overview
6.5.3 Merck Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.5.4 Merck Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.5.5 Merck Animal Health Recent Developments/Updates
6.6 Ceva Animal Health
6.6.1 Ceva Animal Health Corporation Information
6.6.2 Ceva Animal Health Description and Business Overview
6.6.3 Ceva Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.6.4 Ceva Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.6.5 Ceva Animal Health Recent Developments/Updates
6.7 Intervet (AKZO-NOBEL)
6.6.1 Intervet (AKZO-NOBEL) Corporation Information
6.6.2 Intervet (AKZO-NOBEL) Description and Business Overview
6.6.3 Intervet (AKZO-NOBEL) Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Intervet (AKZO-NOBEL) Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.7.5 Intervet (AKZO-NOBEL) Recent Developments/Updates
6.8 SPAH
6.8.1 SPAH Corporation Information
6.8.2 SPAH Description and Business Overview
6.8.3 SPAH Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.8.4 SPAH Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.8.5 SPAH Recent Developments/Updates
6.9 Nanjing Tianbang Biological Technology
6.9.1 Nanjing Tianbang Biological Technology Corporation Information
6.9.2 Nanjing Tianbang Biological Technology Description and Business Overview
6.9.3 Nanjing Tianbang Biological Technology Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.9.4 Nanjing Tianbang Biological Technology Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.9.5 Nanjing Tianbang Biological Technology Recent Developments/Updates
6.10 Sichuan Huapai Bio-pharmaceutical
6.10.1 Sichuan Huapai Bio-pharmaceutical Corporation Information
6.10.2 Sichuan Huapai Bio-pharmaceutical Description and Business Overview
6.10.3 Sichuan Huapai Bio-pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.10.4 Sichuan Huapai Bio-pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.10.5 Sichuan Huapai Bio-pharmaceutical Recent Developments/Updates
6.11 Guangdong Winsun Bio Pharmaceutical
6.11.1 Guangdong Winsun Bio Pharmaceutical Corporation Information
6.11.2 Guangdong Winsun Bio Pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Description and Business Overview
6.11.3 Guangdong Winsun Bio Pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.11.4 Guangdong Winsun Bio Pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.11.5 Guangdong Winsun Bio Pharmaceutical Recent Developments/Updates
6.12 Sichuan Yihe Animal Medicine
6.12.1 Sichuan Yihe Animal Medicine Corporation Information
6.12.2 Sichuan Yihe Animal Medicine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Description and Business Overview
6.12.3 Sichuan Yihe Animal Medicine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.12.4 Sichuan Yihe Animal Medicine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.12.5 Sichuan Yihe Animal Medicine Recent Developments/Updates
6.13 Pulike
6.13.1 Pulike Corporation Information
6.13.2 Pulike Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Description and Business Overview
6.13.3 Pulike Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.13.4 Pulike Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.13.5 Pulike Recent Developments/Updates
6.14 Harbin Pharmaceutical Group Bio-Vaccine
6.14.1 Harbin Pharmaceutical Group Bio-Vaccine Corporation Information
6.14.2 Harbin Pharmaceutical Group Bio-Vaccine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Description and Business Overview
6.14.3 Harbin Pharmaceutical Group Bio-Vaccine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.14.4 Harbin Pharmaceutical Group Bio-Vaccine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.14.5 Harbin Pharmaceutical Group Bio-Vaccine Recent Developments/Updates
6.15 Ringpu
6.15.1 Ringpu Corporation Information
6.15.2 Ringpu Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Description and Business Overview
6.15.3 Ringpu Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.15.4 Ringpu Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.15.5 Ringpu Recent Developments/Updates
6.16 JiLin ZhengYe Biological Products
6.16.1 JiLin ZhengYe Biological Products Corporation Information
6.16.2 JiLin ZhengYe Biological Products Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Description and Business Overview
6.16.3 JiLin ZhengYe Biological Products Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.16.4 JiLin ZhengYe Biological Products Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.16.5 JiLin ZhengYe Biological Products Recent Developments/Updates
6.17 China Animal Husbandry Industry
6.17.1 China Animal Husbandry Industry Corporation Information
6.17.2 China Animal Husbandry Industry Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Description and Business Overview
6.17.3 China Animal Husbandry Industry Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales, Revenue and Gross Margin (2024-2024)
6.17.4 China Animal Husbandry Industry Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product Portfolio
6.17.5 China Animal Husbandry Industry Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Industry Chain Analysis
7.2 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Production Mode & Process
7.4 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales and Marketing
7.4.1 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Channels
7.4.2 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Distributors
7.5 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Customers
8 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Dynamics
8.1 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Industry Trends
8.2 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Drivers
8.3 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Challenges
8.4 Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Competitive Situation by Manufacturers in 2022
Table 4. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses) of Key Manufacturers (2024-2024)
Table 5. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Manufacturers (2024-2024)
Table 6. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue (US$ Million) by Manufacturers (2024-2024)
Table 7. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Share by Manufacturers (2024-2024)
Table 8. Global Market Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Average Price (US$/Dose) of Key Manufacturers (2024-2024)
Table 9. Global Key Players of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Swine Hyopneumoniae Mycoplasma Inactivated Vaccine as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 17. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Region (2024-2024) & (K Doses)
Table 18. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Region (2024-2024)
Table 19. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Region (2024-2034) & (K Doses)
Table 20. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Region (2024-2034)
Table 21. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Region (2024-2024) & (US$ Million)
Table 22. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Region (2024-2024)
Table 23. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Region (2024-2034)
Table 25. North America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 26. North America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2024-2024) & (K Doses)
Table 27. North America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2024-2034) & (K Doses)
Table 28. North America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 29. North America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2024-2024) & (K Doses)
Table 32. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2024-2034) & (K Doses)
Table 33. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 34. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Region: 2024 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Region (2024-2024) & (K Doses)
Table 37. Asia Pacific Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Region (2024-2034) & (K Doses)
Table 38. Asia Pacific Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Region (2024-2024) & (US$ Million)
Table 39. Asia Pacific Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2024-2024) & (K Doses)
Table 42. Latin America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2024-2034) & (K Doses)
Table 43. Latin America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 44. Latin America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2024-2024) & (K Doses)
Table 47. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales by Country (2024-2034) & (K Doses)
Table 48. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2024-2024) & (US$ Million)
Table 49. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses) by Type (2024-2024)
Table 51. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses) by Type (2024-2034)
Table 52. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type (2024-2024)
Table 53. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Type (2024-2034)
Table 54. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue (US$ Million) by Type (2024-2024)
Table 55. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Type (2024-2024)
Table 57. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Type (2024-2034)
Table 58. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Price (US$/Dose) by Type (2024-2024)
Table 59. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Price (US$/Dose) by Type (2024-2034)
Table 60. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses) by Application (2024-2024)
Table 61. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses) by Application (2024-2034)
Table 62. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Application (2024-2024)
Table 63. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Application (2024-2034)
Table 64. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue (US$ Million) by Application (2024-2024)
Table 65. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Application (2024-2024)
Table 67. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Application (2024-2034)
Table 68. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Price (US$/Dose) by Application (2024-2024)
Table 69. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Price (US$/Dose) by Application (2024-2034)
Table 70. Zoetis Animal Health Corporation Information
Table 71. Zoetis Animal Health Description and Business Overview
Table 72. Zoetis Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 73. Zoetis Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 74. Zoetis Animal Health Recent Developments/Updates
Table 75. Boehringer-Ingelheim Corporation Information
Table 76. Boehringer-Ingelheim Description and Business Overview
Table 77. Boehringer-Ingelheim Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 78. Boehringer-Ingelheim Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 79. Boehringer-Ingelheim Recent Developments/Updates
Table 80. Eurovet Corporation Information
Table 81. Eurovet Description and Business Overview
Table 82. Eurovet Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 83. Eurovet Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 84. Eurovet Recent Developments/Updates
Table 85. Hipra Corporation Information
Table 86. Hipra Description and Business Overview
Table 87. Hipra Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 88. Hipra Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 89. Hipra Recent Developments/Updates
Table 90. Merck Animal Health Corporation Information
Table 91. Merck Animal Health Description and Business Overview
Table 92. Merck Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 93. Merck Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 94. Merck Animal Health Recent Developments/Updates
Table 95. Ceva Animal Health Corporation Information
Table 96. Ceva Animal Health Description and Business Overview
Table 97. Ceva Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 98. Ceva Animal Health Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 99. Ceva Animal Health Recent Developments/Updates
Table 100. Intervet (AKZO-NOBEL) Corporation Information
Table 101. Intervet (AKZO-NOBEL) Description and Business Overview
Table 102. Intervet (AKZO-NOBEL) Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 103. Intervet (AKZO-NOBEL) Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 104. Intervet (AKZO-NOBEL) Recent Developments/Updates
Table 105. SPAH Corporation Information
Table 106. SPAH Description and Business Overview
Table 107. SPAH Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 108. SPAH Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 109. SPAH Recent Developments/Updates
Table 110. Nanjing Tianbang Biological Technology Corporation Information
Table 111. Nanjing Tianbang Biological Technology Description and Business Overview
Table 112. Nanjing Tianbang Biological Technology Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 113. Nanjing Tianbang Biological Technology Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 114. Nanjing Tianbang Biological Technology Recent Developments/Updates
Table 115. Sichuan Huapai Bio-pharmaceutical Corporation Information
Table 116. Sichuan Huapai Bio-pharmaceutical Description and Business Overview
Table 117. Sichuan Huapai Bio-pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 118. Sichuan Huapai Bio-pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 119. Sichuan Huapai Bio-pharmaceutical Recent Developments/Updates
Table 120. Guangdong Winsun Bio Pharmaceutical Corporation Information
Table 121. Guangdong Winsun Bio Pharmaceutical Description and Business Overview
Table 122. Guangdong Winsun Bio Pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 123. Guangdong Winsun Bio Pharmaceutical Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 124. Guangdong Winsun Bio Pharmaceutical Recent Developments/Updates
Table 125. Sichuan Yihe Animal Medicine Corporation Information
Table 126. Sichuan Yihe Animal Medicine Description and Business Overview
Table 127. Sichuan Yihe Animal Medicine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 128. Sichuan Yihe Animal Medicine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 129. Sichuan Yihe Animal Medicine Recent Developments/Updates
Table 130. Pulike Corporation Information
Table 131. Pulike Description and Business Overview
Table 132. Pulike Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 133. Pulike Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 134. Pulike Recent Developments/Updates
Table 135. Harbin Pharmaceutical Group Bio-Vaccine Corporation Information
Table 136. Harbin Pharmaceutical Group Bio-Vaccine Description and Business Overview
Table 137. Harbin Pharmaceutical Group Bio-Vaccine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 138. Harbin Pharmaceutical Group Bio-Vaccine Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 139. Harbin Pharmaceutical Group Bio-Vaccine Recent Developments/Updates
Table 140. Ringpu Corporation Information
Table 141. Ringpu Description and Business Overview
Table 142. Ringpu Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 143. Ringpu Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 144. Ringpu Recent Developments/Updates
Table 145. JiLin ZhengYe Biological Products Corporation Information
Table 146. JiLin ZhengYe Biological Products Description and Business Overview
Table 147. JiLin ZhengYe Biological Products Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 148. JiLin ZhengYe Biological Products Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 149. JiLin ZhengYe Biological Products Recent Developments/Updates
Table 150. China Animal Husbandry Industry Corporation Information
Table 151. China Animal Husbandry Industry Description and Business Overview
Table 152. China Animal Husbandry Industry Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2024)
Table 153. China Animal Husbandry Industry Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Product
Table 154. China Animal Husbandry Industry Recent Developments/Updates
Table 155. Key Raw Materials Lists
Table 156. Raw Materials Key Suppliers Lists
Table 157. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Distributors List
Table 158. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Customers List
Table 159. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Trends
Table 160. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Drivers
Table 161. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Challenges
Table 162. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine
Figure 2. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Share by Type in 2022 & 2034
Figure 4. Nasal Spray Product Picture
Figure 5. Chest Injection Product Picture
Figure 6. Intramuscular Injection Product Picture
Figure 7. Intrapulmonary Injection Product Picture
Figure 8. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 9. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Share by Application in 2022 & 2034
Figure 10. Piglets
Figure 11. Adults Pigs
Figure 12. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 13. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Size (2024-2034) & (US$ Million)
Figure 14. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales (2024-2034) & (K Doses)
Figure 15. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Average Price (US$/Dose) & (2024-2034)
Figure 16. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Report Years Considered
Figure 17. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Share by Manufacturers in 2022
Figure 18. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Players: Market Share by Revenue in 2022
Figure 20. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 21. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Figure 22. North America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country (2024-2034)
Figure 23. North America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Country (2024-2034)
Figure 24. United States Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 25. Canada Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 26. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country (2024-2034)
Figure 27. Europe Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Country (2024-2034)
Figure 28. Germany Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 29. France Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 30. U.K. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 31. Italy Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 32. Russia Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 33. Asia Pacific Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Region (2024-2034)
Figure 34. Asia Pacific Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Region (2024-2034)
Figure 35. China Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 36. Japan Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 37. South Korea Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 38. India Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 39. Australia Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 40. China Taiwan Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 41. Southeast Asia Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 42. Latin America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country (2024-2034)
Figure 43. Latin America Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Country (2024-2034)
Figure 44. Mexico Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 45. Brazil Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 46. Argentina Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 47. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Sales Market Share by Country (2024-2034)
Figure 48. Middle East & Africa Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Market Share by Country (2024-2034)
Figure 49. Turkey Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 50. Saudi Arabia Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 51. UAE Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 52. Global Sales Market Share of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine by Type (2024-2034)
Figure 53. Global Revenue Market Share of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine by Type (2024-2034)
Figure 54. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Price (US$/Dose) by Type (2024-2034)
Figure 55. Global Sales Market Share of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine by Application (2024-2034)
Figure 56. Global Revenue Market Share of Swine Hyopneumoniae Mycoplasma Inactivated Vaccine by Application (2024-2034)
Figure 57. Global Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Price (US$/Dose) by Application (2024-2034)
Figure 58. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Value Chain
Figure 59. Swine Hyopneumoniae Mycoplasma Inactivated Vaccine Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed